AngioDynamics, Inc. (NASDAQ:ANGO) Receives $19.33 Average Target Price from Brokerages

Shares of AngioDynamics, Inc. (NASDAQ:ANGOGet Free Report) have been assigned an average rating of “Moderate Buy” from the five analysts that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $19.3333.

ANGO has been the subject of several research reports. Zacks Research raised shares of AngioDynamics from a “hold” rating to a “strong-buy” rating in a research report on Friday, January 9th. Wall Street Zen cut shares of AngioDynamics from a “buy” rating to a “hold” rating in a report on Sunday, December 21st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research report on Wednesday, January 21st.

View Our Latest Research Report on ANGO

Institutional Trading of AngioDynamics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Farther Finance Advisors LLC lifted its position in shares of AngioDynamics by 146.4% during the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 1,199 shares in the last quarter. State of Wyoming raised its stake in AngioDynamics by 53.6% during the 3rd quarter. State of Wyoming now owns 4,749 shares of the medical instruments supplier’s stock worth $53,000 after acquiring an additional 1,658 shares during the period. State of Alaska Department of Revenue purchased a new position in AngioDynamics during the third quarter valued at approximately $25,000. Washington Trust Advisors Inc. bought a new position in shares of AngioDynamics in the third quarter worth approximately $27,000. Finally, Rhumbline Advisers increased its stake in shares of AngioDynamics by 4.3% in the second quarter. Rhumbline Advisers now owns 61,337 shares of the medical instruments supplier’s stock worth $608,000 after purchasing an additional 2,510 shares in the last quarter. Hedge funds and other institutional investors own 89.43% of the company’s stock.

AngioDynamics Price Performance

NASDAQ ANGO opened at $10.67 on Friday. The stock has a market capitalization of $439.82 million, a price-to-earnings ratio of -15.93 and a beta of 0.52. AngioDynamics has a 1-year low of $8.27 and a 1-year high of $13.99. The business’s fifty day moving average price is $11.82 and its 200-day moving average price is $11.17.

About AngioDynamics

(Get Free Report)

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.

Further Reading

Analyst Recommendations for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.